Please ensure Javascript is enabled for purposes of website accessibility

5-Star Stocks Poised to Pop: Johnson & Johnson

By Brian D. Pacampara, CFA - Updated Apr 5, 2017 at 8:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Market-trouncing returns could be written in this five-star stock.

Based on the aggregated intelligence of 120,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health-care-products giant Johnson & Johnson (NYSE:JNJ) has earned a coveted five-star ranking. Our data has shown that five-star stocks outperform the market by a significant margin; conversely, one-star stocks have woefully lagged the market average.

With that in mind, let's take a closer look at Johnson & Johnson's business, and see what CAPS investors are saying about the stock right now.

Johnson & Johnson facts

Headquarters (founded)

New Brunswick, N.J. (1885)

Market Cap

$163.4 billion


Pharmaceuticals / health care

TTM Revenue

$64.5 billion


CEO William Weldon (since 2002)
CFO Dominic Caruso (since 2007)


Band-Aid, Listerine, Sudafed, Tylenol

Return on Equity (average last three years)


Dividend Yield



Merck (NYSE:MRK)
Eli Lilly (NYSE:LLY)

CAPS members bullish on JNJ also bullish on

Procter & Gamble (NYSE:PG)
General Electric (NYSE:GE)

CAPS members bearish on JNJ also bearish on

Microsoft (NASDAQ:MSFT)
General Motors (NYSE:GM)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, fully 2,615 of the 2,677 All-Star members who have rated Johnson & Johnson -- some 97% -- believe the stock will outperform the S&P 500 going forward. These bulls include hazelnut283 and rd80, both of whom are ranked in the top 10% of our community.

Late last month, hazelnut283 noted that the stock "has become a rare, relatively stable beacon in the sea of chaos. A good dividend, and tons of foreign exposure (re: even kids in India and China use JNJ products daily), make this one for the long-term."

In a more recent pitch from last week, rd80 shares that sentiment, tapping Johnson & Johnson as an ideal way to play defense

Pharma, medical supplies, and consumer staples. JNJ has nice dividend yield and strong track record of raising the dividend year after year. The company's balance sheet is net cash positive, meaning if credit markets totally seized up, they could continue operating by paying off debt rather than rolling it over.

JNJ products will continue to be sold even in a bad economy, so the company has good earnings visibility - a rarity right now. PE is low, earnings are likely to continue growing at slow-to-moderate rates and investors get paid to hold the stock.

When the economy starts to recover, JNJ will lag the market. But, until then, it's one of the few reliable, predictable safe investments around.

What do you think about Johnson & Johnson, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 120,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson and Eli Lilly are Motley Fool Income Investor picks. Microsoft is an Inside Value selection. The Fool's disclosure policy always gets a perfect score.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$165.30 (-1.10%) $-1.84
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$91.02 (2.35%) $2.09
Microsoft Corporation Stock Quote
Microsoft Corporation
$291.91 (1.70%) $4.89
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$308.08 (2.63%) $7.89
General Electric Company Stock Quote
General Electric Company
$79.93 (1.30%) $1.03
General Motors Company Stock Quote
General Motors Company
$39.48 (2.65%) $1.02
The Procter & Gamble Company Stock Quote
The Procter & Gamble Company
$146.67 (0.97%) $1.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.